Global Respiratory Syncytial Virus Therapeutics Market is expected to grow at a CAGR of 31.20% during the forecast period to reach US$ 7001.1 Mn. by 2029.Respiratory Syncytial Virus Therapeutics Market Drivers and Restrains:
Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory infections such as bronchiolitis and pneumonia. The increasing cases of RSV infections are fueling the demand for rapid diagnostic methods globally. Rise in prevalence of RSV infection among infants and the increasing interest of different biotechnology companies to develop various recombinant drugs to treat RSV infection are impel the respiratory syncytial virus (RSV) therapeutics market from in the near future.To know about the Research Methodology:- Request Free Sample Report The major driving factors of the respiratory syncytial virus therapeutics market such as increasing incidence rate of respiratory infections, growing demand for in-vitro diagnostics, and increasing demand facilities like care taken during treatment. RSV is a common cause of bronchiolitis and pneumonia in babies. RSV is spread from respiratory emissions through close contact with infected persons. The unavailability of approved drug or vaccine has been made accessible to treat or prevent RSV infection till date. Patients are treated only by administering prophylaxis drugs. Manufacturers are focusing on the development of new drugs and vaccines with better efficacy, which is likely to fuel the respiratory syncytial virus (RSV) therapeutics market in the upcoming period. The current shortage of specific treatment options, the development of vaccines for RSV in the future, the high price of prophylaxis drugs, lack of efficacy of the drugs and resistance against RSV infection are factors that are likely to hamper this segment. There are several unmet needs in market and biologics, which provides lucrative opportunities for existing players and new entrants in the global market.
Segmentation Analysis:
Based on the causative virus, the market has been segmented into respiratory syncytial viruses (RSV) infectious, influenza virus’s infectious, parainfluenza viruses infectious, adenoviruses infectious, rhinoviruses infectious. The Respiratory syncytial virus infectious segment accounts for a major share of the respiratory virus infection drugs market in 2022. The RSV is most common type of respiratory virus infection, while parainfluenza, adenoviruses, and rhinoviruses fall into the less common forms. According to the World Health Organization, almost xx million people are infected and nearly xx% deaths caused because of respiratory syncytial virus, yearly. Based on the distribution channel, the market has been segmented into hospital pharmacies, drug stores, retail pharmacies, clinics. The hospital pharmacies segment is expected to grow at CAGR of xx% during the forecast period. Emphasis on establishing hospitals as primary care providers. Several state-of-art hospital chains globally, owing to the rising government funds, and improving availability to medicines at reasonable prices are help to the hospital pharmacy segment to retain its strong market position during the forecast period.Regional Analysis:
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the prominent share of market in 2022 owing to the high level of research activity in the U.S., high awareness and easily available diagnostic tests. Furthermore, presence of several key players has led to increased investment in research and development of anti RSV drugs. Therefore, presence of these players are projected to propel the syncytial virus (RSV) therapeutics market in North America at a rapid pace during the forecast period. According to the U.S., Department of Health & Human Services, nearly xx% of the children infected with RSV were under two-years of the age, worldwide. Asia Pacific is expected to grow at the largest CAGR of xx% during the forecast period. Lack of appropriate population-based studies in emerging countries could challenge the valuation of respiratory-related virus infections. Pharmaceutical research and development spending in developing markets such as China and India is rising, which is driving the growth of the Asia Pacific respiratory syncytial virus (RSV) therapeutics market.Respiratory Syncytial Virus Therapeutics Market Competitive landscape
Major Key players operating in this market are AstraZeneca, AbbVie, Ablynx NV, ADMA Biologics, Alnylam Pharmaceuticals, and Ark Biosciences. Manufacturers in the respiratory syncytial virus therapeutics are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. The objective of the report is to present comprehensive analysis of market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global market dynamics, structure by analyzing the market segments, and project the market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the market make the report investor’s guide.Respiratory Syncytial Virus Therapeutics Market Scope: Inquire before buying
Global Respiratory Syncytial Virus Therapeutics Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US$ 1046 Mn. Forecast Period 2023 to 2029 CAGR: 31.2% Market Size in 2029: US$ 7001.1 Mn. Segments Covered: by Type of Causative Virus Respiratory syncytial viruses (RSV) infectious Influenza viruses infectious Parainfluenza viruses infectious Adenoviruses infectious Rhinoviruses infectious by Distribution Channel Hospital pharmacies Drug stores Retail pharmacies Clinics Respiratory Syncytial Virus Therapeutics Market, by Region:
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Respiratory Syncytial Virus Therapeutics Market, Key Players:
1. AstraZeneca 2. AbbVie 3. Ablynx NV 4. ADMA Biologics 5. Alnylam Pharmaceuticals 6. Ark Biosciences 7. ImmunoVaccine Technologies 8. Aviragen Therapeutics 9. Boehringer Ingelheim 10. Bavarian Nordic 11. Gilead Sciences 12. Johnson & Johnson 13. Kyowa Hakko Kirin 14. Mymetics Corporation 15. GlaxoSmithKline plc. 16. Teva Pharmaceutical 17. Vaxart 18. Dickinson and Company 19. Novartis Diagnostics 20. Abbott Laboratories 21. Ortho Clinical Diagnostics 22. Thermo Fisher Scientific Inc. 23. Bio-Rad Laboratories Inc. 24. Hoffmann La Roche Limited Frequently Asked Questions: 1. Which region has the largest share in Global Respiratory Syncytial Virus Therapeutics Market? Ans: North America region holds the highest share in 2022. 2. What is the growth rate of Global Respiratory Syncytial Virus Therapeutics Market? Ans: The Global Respiratory Syncytial Virus Therapeutics Market is growing at a CAGR of 31.2% during forecasting period 2023-2029. 3. What is scope of the Global Respiratory Syncytial Virus Therapeutics market report? Ans: Global Respiratory Syncytial Virus Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Respiratory Syncytial Virus Therapeutics market? Ans: The important key players in the Global Respiratory Syncytial Virus Therapeutics Market are – AstraZeneca, AbbVie, Ablynx NV, ADMA Biologics, Alnylam Pharmaceuticals, Ark Biosciences, ImmunoVaccine Technologies, Aviragen Therapeutics, Boehringer Ingelheim, Bavarian Nordic, Gilead Sciences, Johnson & Johnson, Kyowa Hakko Kirin, Mymetics Corporation, GlaxoSmithKline plc., and Teva Pharmaceutical. 5. What is the study period of this market? Ans: The Global Respiratory Syncytial Virus Therapeutics Market is studied from 2022 to 2029.
Respiratory Syncytial Virus Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Respiratory Syncytial Virus Therapeutics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Respiratory Syncytial Virus Therapeutics Market Analysis and Forecast 6.1. Global Respiratory Syncytial Virus Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Respiratory Syncytial Virus Therapeutics Market Analysis and Forecast, by Type of Causative Virus 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Type of Causative Virus 7.4. Global Respiratory Syncytial Virus Therapeutics Market Size (US$ Bn) Forecast, by Type of Causative Virus 7.5. Global Respiratory Syncytial Virus Therapeutics Market Analysis, by Type of Causative Virus 7.6. Global Respiratory Syncytial Virus Therapeutics Market Attractiveness Analysis, by Type of Causative Virus 8. Global Respiratory Syncytial Virus Therapeutics Market Analysis and Forecast, by Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Distribution Channel 8.4. Global Respiratory Syncytial Virus Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel 8.5. Global Respiratory Syncytial Virus Therapeutics Market Analysis, by Distribution Channel 8.6. Global Respiratory Syncytial Virus Therapeutics Market Attractiveness Analysis, by Distribution Channel 9. Global Respiratory Syncytial Virus Therapeutics Market Analysis, by Region 9.1. Global Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Region 9.2. Global Respiratory Syncytial Virus Therapeutics Market Size (US$ Bn) Forecast, by Region 9.3. Global Respiratory Syncytial Virus Therapeutics Market Attractiveness Analysis, by Region 10. North America Respiratory Syncytial Virus Therapeutics Market Analysis 10.1. Key Findings 10.2. North America Respiratory Syncytial Virus Therapeutics Market Overview 10.3. North America Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Type of Causative Virus 10.4. North America Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 10.4.1. Respiratory syncytial viruses (RSV) infectious 10.4.2. Influenza viruses infectious 10.4.3. Parainfluenza viruses infectious 10.4.4. Adenoviruses infectious 10.4.5. Rhinoviruses infectious 10.5. North America Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Distribution Channel 10.6. North America Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 10.6.1. Hospital pharmacies 10.6.2. Drug stores 10.6.3. Retail pharmacies 10.6.4. Clinics 10.7. North America Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Country 10.8. North America Respiratory Syncytial Virus Therapeutics Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Respiratory Syncytial Virus Therapeutics Market Analysis, by Country 10.10. U.S. Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 10.10.1. Respiratory syncytial viruses (RSV) infectious 10.10.2. Influenza viruses infectious 10.10.3. Parainfluenza viruses infectious 10.10.4. Adenoviruses infectious 10.10.5. Rhinoviruses infectious 10.11. U.S. Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 10.11.1. Hospital pharmacies 10.11.2. Drug stores 10.11.3. Retail pharmacies 10.11.4. Clinics 10.12. Canada Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 10.12.1. Respiratory syncytial viruses (RSV) infectious 10.12.2. Influenza viruses infectious 10.12.3. Parainfluenza viruses infectious 10.12.4. Adenoviruses infectious 10.12.5. Rhinoviruses infectious 10.13. Canada Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 10.13.1. Hospital pharmacies 10.13.2. Drug stores 10.13.3. Retail pharmacies 10.13.4. Clinics 10.14. North America Respiratory Syncytial Virus Therapeutics Market Attractiveness Analysis 10.14.1. By Type of Causative Virus 10.14.2. By Distribution Channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Respiratory Syncytial Virus Therapeutics Market Analysis 11.1. Key Findings 11.2. Europe Respiratory Syncytial Virus Therapeutics Market Overview 11.3. Europe Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Type of Causative Virus 11.4. Europe Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 11.4.1. Respiratory syncytial viruses (RSV) infectious 11.4.2. Influenza viruses infectious 11.4.3. Parainfluenza viruses infectious 11.4.4. Adenoviruses infectious 11.4.5. Rhinoviruses infectious 11.5. Europe Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Distribution Channel 11.6. Europe Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 11.6.1. Hospital pharmacies 11.6.2. Drug stores 11.6.3. Retail pharmacies 11.6.4. Clinics 11.7. Europe Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Country 11.8. Europe Respiratory Syncytial Virus Therapeutics Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Respiratory Syncytial Virus Therapeutics Market Analysis, by Country 11.10. Germany Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 11.10.1. Respiratory syncytial viruses (RSV) infectious 11.10.2. Influenza viruses infectious 11.10.3. Parainfluenza viruses infectious 11.10.4. Adenoviruses infectious 11.10.5. Rhinoviruses infectious 11.11. Germany Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 11.11.1. Hospital pharmacies 11.11.2. Drug stores 11.11.3. Retail pharmacies 11.11.4. Clinics 11.12. U.K. Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 11.12.1. Respiratory syncytial viruses (RSV) infectious 11.12.2. Influenza viruses infectious 11.12.3. Parainfluenza viruses infectious 11.12.4. Adenoviruses infectious 11.12.5. Rhinoviruses infectious 11.13. U.K. Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 11.13.1. Hospital pharmacies 11.13.2. Drug stores 11.13.3. Retail pharmacies 11.13.4. Clinics 11.14. France Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 11.14.1. Respiratory syncytial viruses (RSV) infectious 11.14.2. Influenza viruses infectious 11.14.3. Parainfluenza viruses infectious 11.14.4. Adenoviruses infectious 11.14.5. Rhinoviruses infectious 11.15. France Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 11.15.1. Hospital pharmacies 11.15.2. Drug stores 11.15.3. Retail pharmacies 11.15.4. Clinics 11.16. Italy Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 11.16.1. Respiratory syncytial viruses (RSV) infectious 11.16.2. Influenza viruses infectious 11.16.3. Parainfluenza viruses infectious 11.16.4. Adenoviruses infectious 11.16.5. Rhinoviruses infectious 11.17. Italy Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 11.17.1. Hospital pharmacies 11.17.2. Drug stores 11.17.3. Retail pharmacies 11.17.4. Clinics 11.18. Spain Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 11.18.1. Respiratory syncytial viruses (RSV) infectious 11.18.2. Influenza viruses infectious 11.18.3. Parainfluenza viruses infectious 11.18.4. Adenoviruses infectious 11.18.5. Rhinoviruses infectious 11.19. Spain Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 11.19.1. Hospital pharmacies 11.19.2. Drug stores 11.19.3. Retail pharmacies 11.19.4. Clinics 11.20. Rest of Europe Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 11.20.1. Respiratory syncytial viruses (RSV) infectious 11.20.2. Influenza viruses infectious 11.20.3. Parainfluenza viruses infectious 11.20.4. Adenoviruses infectious 11.20.5. Rhinoviruses infectious 11.21. Rest of Europe Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 11.21.1. Hospital pharmacies 11.21.2. Drug stores 11.21.3. Retail pharmacies 11.21.4. Clinics 11.22. Europe Respiratory Syncytial Virus Therapeutics Market Attractiveness Analysis 11.22.1. By Type of Causative Virus 11.22.2. By Distribution Channel 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Analysis 12.1. Key Findings 12.2. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Overview 12.3. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Type of Causative Virus 12.4. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 12.4.1. Respiratory syncytial viruses (RSV) infectious 12.4.2. Influenza viruses infectious 12.4.3. Parainfluenza viruses infectious 12.4.4. Adenoviruses infectious 12.4.5. Rhinoviruses infectious 12.5. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Distribution Channel 12.6. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 12.6.1. Hospital pharmacies 12.6.2. Drug stores 12.6.3. Retail pharmacies 12.6.4. Clinics 12.7. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Country 12.8. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Analysis, by Country 12.10. China Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 12.10.1. Respiratory syncytial viruses (RSV) infectious 12.10.2. Influenza viruses infectious 12.10.3. Parainfluenza viruses infectious 12.10.4. Adenoviruses infectious 12.10.5. Rhinoviruses infectious 12.11. China Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 12.11.1. Hospital pharmacies 12.11.2. Drug stores 12.11.3. Retail pharmacies 12.11.4. Clinics 12.12. India Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 12.12.1. Respiratory syncytial viruses (RSV) infectious 12.12.2. Influenza viruses infectious 12.12.3. Parainfluenza viruses infectious 12.12.4. Adenoviruses infectious 12.12.5. Rhinoviruses infectious 12.13. India Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 12.13.1. Hospital pharmacies 12.13.2. Drug stores 12.13.3. Retail pharmacies 12.13.4. Clinics 12.14. Japan Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 12.14.1. Respiratory syncytial viruses (RSV) infectious 12.14.2. Influenza viruses infectious 12.14.3. Parainfluenza viruses infectious 12.14.4. Adenoviruses infectious 12.14.5. Rhinoviruses infectious 12.15. Japan Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 12.15.1. Hospital pharmacies 12.15.2. Drug stores 12.15.3. Retail pharmacies 12.15.4. Clinics 12.16. ASEAN Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 12.16.1. Respiratory syncytial viruses (RSV) infectious 12.16.2. Influenza viruses infectious 12.16.3. Parainfluenza viruses infectious 12.16.4. Adenoviruses infectious 12.16.5. Rhinoviruses infectious 12.17. ASEAN Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 12.17.1. Hospital pharmacies 12.17.2. Drug stores 12.17.3. Retail pharmacies 12.17.4. Clinics 12.18. Rest of Asia Pacific Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 12.18.1. Respiratory syncytial viruses (RSV) infectious 12.18.2. Influenza viruses infectious 12.18.3. Parainfluenza viruses infectious 12.18.4. Adenoviruses infectious 12.18.5. Rhinoviruses infectious 12.19. Rest of Asia Pacific Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 12.19.1. Hospital pharmacies 12.19.2. Drug stores 12.19.3. Retail pharmacies 12.19.4. Clinics 12.20. Asia Pacific Respiratory Syncytial Virus Therapeutics Market Attractiveness Analysis 12.20.1. By Type of Causative Virus 12.20.2. By Distribution Channel 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Overview 13.3. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Type of Causative Virus 13.4. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 13.4.1. Respiratory syncytial viruses (RSV) infectious 13.4.2. Influenza viruses infectious 13.4.3. Parainfluenza viruses infectious 13.4.4. Adenoviruses infectious 13.4.5. Rhinoviruses infectious 13.5. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Distribution Channel 13.6. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 13.6.1. Hospital pharmacies 13.6.2. Drug stores 13.6.3. Retail pharmacies 13.6.4. Clinics 13.7. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Country 13.8. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Analysis, by Country 13.10. GCC Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 13.10.1. Respiratory syncytial viruses (RSV) infectious 13.10.2. Influenza viruses infectious 13.10.3. Parainfluenza viruses infectious 13.10.4. Adenoviruses infectious 13.10.5. Rhinoviruses infectious 13.11. GCC Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 13.11.1. Hospital pharmacies 13.11.2. Drug stores 13.11.3. Retail pharmacies 13.11.4. Clinics 13.12. South Africa Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 13.12.1. Respiratory syncytial viruses (RSV) infectious 13.12.2. Influenza viruses infectious 13.12.3. Parainfluenza viruses infectious 13.12.4. Adenoviruses infectious 13.12.5. Rhinoviruses infectious 13.13. South Africa Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 13.13.1. Hospital pharmacies 13.13.2. Drug stores 13.13.3. Retail pharmacies 13.13.4. Clinics 13.14. Rest of Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 13.14.1. Respiratory syncytial viruses (RSV) infectious 13.14.2. Influenza viruses infectious 13.14.3. Parainfluenza viruses infectious 13.14.4. Adenoviruses infectious 13.14.5. Rhinoviruses infectious 13.15. Rest of Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 13.15.1. Hospital pharmacies 13.15.2. Drug stores 13.15.3. Retail pharmacies 13.15.4. Clinics 13.16. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market Attractiveness Analysis 13.16.1. By Type of Causative Virus 13.16.2. By Distribution Channel 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Respiratory Syncytial Virus Therapeutics Market Analysis 14.1. Key Findings 14.2. South America Respiratory Syncytial Virus Therapeutics Market Overview 14.3. South America Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Type of Causative Virus 14.4. South America Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 14.4.1. Respiratory syncytial viruses (RSV) infectious 14.4.2. Influenza viruses infectious 14.4.3. Parainfluenza viruses infectious 14.4.4. Adenoviruses infectious 14.4.5. Rhinoviruses infectious 14.5. South America Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Distribution Channel 14.6. South America Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 14.6.1. Hospital pharmacies 14.6.2. Drug stores 14.6.3. Retail pharmacies 14.6.4. Clinics 14.7. South America Respiratory Syncytial Virus Therapeutics Market Value Share Analysis, by Country 14.8. South America Respiratory Syncytial Virus Therapeutics Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 14.9.1. Respiratory syncytial viruses (RSV) infectious 14.9.2. Influenza viruses infectious 14.9.3. Parainfluenza viruses infectious 14.9.4. Adenoviruses infectious 14.9.5. Rhinoviruses infectious 14.10. Brazil Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 14.10.1. Hospital pharmacies 14.10.2. Drug stores 14.10.3. Retail pharmacies 14.10.4. Clinics 14.11. Mexico Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 14.11.1. Respiratory syncytial viruses (RSV) infectious 14.11.2. Influenza viruses infectious 14.11.3. Parainfluenza viruses infectious 14.11.4. Adenoviruses infectious 14.11.5. Rhinoviruses infectious 14.12. Mexico Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 14.12.1. Hospital pharmacies 14.12.2. Drug stores 14.12.3. Retail pharmacies 14.12.4. Clinics 14.13. Rest of South America Respiratory Syncytial Virus Therapeutics Market Forecast, by Type of Causative Virus 14.13.1. Respiratory syncytial viruses (RSV) infectious 14.13.2. Influenza viruses infectious 14.13.3. Parainfluenza viruses infectious 14.13.4. Adenoviruses infectious 14.13.5. Rhinoviruses infectious 14.14. Rest of South America Respiratory Syncytial Virus Therapeutics Market Forecast, by Distribution Channel 14.14.1. Hospital pharmacies 14.14.2. Drug stores 14.14.3. Retail pharmacies 14.14.4. Clinics 14.15. South America Respiratory Syncytial Virus Therapeutics Market Attractiveness Analysis 14.15.1. By Type of Causative Virus 14.15.2. By Distribution Channel 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. AstraZeneca 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. AbbVie 15.3.3. Ablynx NV 15.3.4. ADMA Biologics 15.3.5. Alnylam Adenoviruses infectious 15.3.6. Ark Biosciences 15.3.7. ImmunoVaccine Technologies 15.3.8. Aviragen Therapeutics 15.3.9. Boehringer Ingelheim 15.3.10. Bavarian Nordic 15.3.11. Gilead Sciences 15.3.12. Johnson & Johnson 15.3.13. Kyowa Hakko Kirin 15.3.14. Mymetics Corporation 15.3.15. GlaxoSmithKline plc. 15.3.16. Teva Pharmaceutical 15.3.17. Vaxart 15.3.18. Dickinson and Company 15.3.19. Novartis Diagnostics 15.3.20. Abbott Laboratories 15.3.21. Ortho Clinical Diagnostics 15.3.22. Thermo Fisher Scientific Inc. 15.3.23. Bio-Rad Laboratories Inc. 15.3.24. Hoffmann La Roche Limited 16. Primary Key Insights